Skip to main content

Posts

Showing posts with the label therapies

Solar plane lands in New York City

A solar-powered airplane finished crossing the United States on Saturday, landing in New York City after flying over the Statue of Liberty during its historic bid to circle the globe, the project team said.  The spindly, single-seat experimental aircraft, dubbed Solar Impulse 2, arrived at New York's John F. Kennedy International Airport at about 4 a.m. local time after it took off about five hours beforehand at Lehigh Valley International Airport in Pennsylvania, the team reported on the airplane's website.  Such a pleasure to land in New York! For the 14th time we celebrate sustainability," said the project's co-founder Andre Borschberg on Twitter after flying over the city and the Statue of Liberty during the 14th leg of the trip around the globe. The Swiss team flying the aircraft in a campaign to build support for clean energy technologies hopes eventually to complete its circumnavigation in Abu Dhabi, where the journey began in March 2015. The solar cr...

Two new therapies of advanced kidney cancer could change treatment of the disease, say experts

Both drugs increased survival in trials which are also published in the New England Journal of Medicine.One drug takes the brakes off the immune system while the other stops growth signals in the tumour.  Cancer Research UK said the developments will "greatly expand the arsenal" of available drugs.  Kidney cancer is the eighth most common cancer in the UK and survival rates plummet if it is caught late.  Once the tumour has spread to other parts of the body then only one-in-10 people live for five years after diagnosis.  It's another big day for immunotherapy for cancerDr James Larkin, Royal Marsden Hospital The first trial, called Checkmate 025, used the immunotherapy drug  nivolumab.  It is one of a suite of "checkpoint inhibitors" being developed by pharmaceutical companies that stop cancers turning off the immune system.  They have already been proven effective in skin and lung cancers.  The trial on 821 patients showed average...